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ABSTRACT     
 
Patients with inherited thrombocytopenias often require platelet transfusions to raise platelet count before 
surgery or other invasive procedures; moreover, subjects presenting clinically significant spontaneous 
bleeding may benefit from an enduring improvement of thrombocytopenia. The hypothesis that 
thrombopoietin-mimetics can increase platelet count in inherited thrombocytopenias is appealing, but 
evidence is scarce. We conducted a prospective, phase 2 clinical trial to investigate the efficacy of the oral 
thrombopoietin-mimetic eltrombopag in different forms of inherited thrombocytopenia. We enrolled 24 
patients affected with MYH9-related disease, ANKRD26-related thrombocytopenia, X-linked 
thrombocytopenia/Wiskott-Aldrich syndrome, monoallelic Bernard-Soulier syndrome, or ITGB3-related 
thrombocytopenia. Average pre-treatment platelet count was 40.4 x10
9
/L. Patients received a 3- to 6-week 
course of eltrombopag in a dose-escalation manner. Of 23 patients evaluable for response, 11 (47.8%) 
achieved a major response (platelet count >100 x10
9
/L), 10 (43.5%) a minor response (platelet count at 
least twice than baseline), whereas 2 patients (8.7%) did not respond. Average increase of platelet count 
compared to baseline was 64.5 x10
9
/L (p<0.001). Four patients who presented clinically significant 
spontaneous bleeding were admitted to a long-term eltrombopag administration (16 additional weeks): all 
of them obtained remission of mucosal hemorrhages that persisted throughout the treatment period. 
Treatment was globally well tolerated: 5 patients reported mild adverse events and one patient a moderate 
adverse event. In conclusion, eltrombopag was safe and effective in increasing platelet count and reducing 
bleeding symptoms in different forms of inherited thrombocytopenia. Despite these encouraging results, 
caution is recommended when using thrombopoietin-mimetics in inherited thrombocytopenias 
predisposing to leukemia. ClinicalTrials.gov identifier: NCT02422394. 
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INTRODUCTION     
 
Inherited thrombocytopenias (ITs) are a heterogeneous group of disorders characterized by a reduced 
number of blood platelets that can result in a bleeding tendency of variable severity. Although ITs are rare, 
recent improvements in the knowledge of these conditions have indicated that, taken together, their 
prevalence is higher than previously thought. In fact, based on a registry of patients with 
thrombocytopenia, the prevalence of ITs in the Italian population is estimated to be 2.7 per 100,000.
1 
 
 
Most patients with ITs present mild or no spontaneous bleeding: however, even patients who do not have 
spontaneous hemorrhages often require platelet transfusions prior to surgery or other invasive procedures 
because their platelet count is below the safe threshold for the specific procedure.
1-5
 Platelet transfusions 
have several drawbacks, as they expose patients to the risk of acute reactions, transmission of infectious 
diseases, and alloimmunization with consequent refractoriness to subsequent platelet transfusions.
3,6,7
 The 
latter is a particularly critical event in these patients with lifelong thrombocytopenia. Moreover, the 
availability of platelet units is affected by the scarceness of blood donors. Conversely, some IT patients 
present frequent episodes of spontaneous bleeding that affect their quality of life, expose them to the risk 
of major hemorrhages, and may require frequent hospitalization and/or transfusions. In these subjects, 
obtaining an enduring increase of platelet count sufficient to stably abolish or reduce spontaneous 
hemorrhages would be a major achievement.  
 
Thrombopoietin (TPO)-receptor agonists (TPO-RAs) are targeted agents that can stimulate 
megakaryopoiesis and platelet production through the activation of the TPO receptor, MPL. These drugs 
are currently approved for the treatment of a few forms of acquired thrombocytopenia.
8 
Although the 
hypothesis that TPO-RAs can increase platelet count also in patients with ITs is appealing, the evidence on 
this topic is very scarce, mainly due to the difficulties in carrying out clinical trials in these orphan diseases. 
As a matter of fact, only one prospective study has been conducted so far: moreover, it enrolled patients 
affected with only one of the many forms of ITs. In this trial, a short course of the oral TPO-RA eltrombopag 
was given to 12 patients with the thrombocytopenia deriving from mutations in MYH9 (MYH9-related 
disease, MYH9-RD): 11 patients showed an increase of platelet count.
9
 Based on these results, short-term 
eltrombopag was used anecdotally to prepare MYH9-RD patients for major surgery.
10-12
 The remaining 
available clinical information on the effects of TPO-RAs in ITs derives from single case reports
13-17 
and the 
retrospective investigation of one small case series.
18
  
 
Here we report the results of the second prospective clinical trial on TPO-RAs in genetic 
thrombocytopenias. We investigated the efficacy of eltrombopag in increasing platelet count in patients 
4 
 
affected by different forms of IT. Patients received short-term eltrombopag to test if this treatment can 
raise platelet count up to safe levels for major surgery. Moreover, in those patients presenting with 
clinically significant spontaneous bleeding, we also tested if a prolonged administration of eltrombopag can 
induce a persistent remission of the spontaneous hemorrhages. 
 
METHODS 
 
Patients 
 
Patients were enrolled at 5 Italian centres (Supplemental Table S1). The study protocol was approved by 
the institutional review boards of all centres. Patients or their legal guardians signed written informed 
consent for the study, which was conducted according to the Declaration of Helsinki.  
Inclusion and exclusion criteria for this trial are detailed in Supplemental Methods.  
 
Study design 
 
This was a phase 2, open-label, dose-escalation trial. The study consisted of two Parts.  
 
Part 1. The main aim of Part 1 was to test whether, and in which forms of IT, a short-term course of 
eltrombopag is effective in increasing platelet count above the safe threshold for all types of surgery (100 
x10
9
/L).
4,5
 All patients eligible for the study entered the Part 1. Patients received eltrombopag 50 mg/day 
for 3 weeks. Patients who obtained a platelet count >100 x10
9
/L at day 21 stopped treatment (as they 
achieved the primary endpoint). In the other cases, patients received eltrombopag 75 mg/day for 3 
additional weeks.   
 
Part 2. The main aim of Part 2 was to test the efficacy of long-term eltrombopag in achieving an enduring 
remission of bleeding symptoms in patients presenting with clinically significant spontaneous hemorrhages. 
Criteria for entering the Part 2 were the following: patients with spontaneous bleeding at baseline grade ≥2 
according to the World Health Organization (WHO) bleeding scale, who completed Part 1 without severe 
side effects and obtained a reduction of bleeding symptoms at the end of Part 1. Part 2 consisted of 16 
weeks of treatment. Patients were started on eltrombopag 25 mg/day. Then, they were re-evaluated every 
4 weeks, and eltrombopag dose was adjusted based on bleeding tendency and platelet count according to 
the schedule reported in Supplemental Figure S1.  
 
Endpoints and outcome measures 
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The primary endpoint of Part 1 was the achievement of a platelet count >100 x10
9
/L, i.e. the safe level for 
all types of surgery according to current guidelines.
4,5
 Major response was defined as the achievement of 
the primary endpoint. Minor response was defined as the achievement of a platelet count at least two-fold 
higher than baseline without reaching the criteria for major response.  
The primary endpoint of Part 2 was the stable reduction of spontaneous bleeding manifestations according 
to the WHO bleeding scale during the last 2 weeks of treatment. Major response was defined as a complete 
remission of hemorrhages. Minor response was defined as a reduction of bleeding according to the WHO 
bleeding scale without reaching the criteria for major response.  
Secondary endpoints included safety and tolerability of the treatments; dosages of eltrombopag required 
for achieving the primary endpoints; improvement of health-related quality of life (HR-QoL) with long-term 
eltrombopag administration (Part 2 only).  
Exploratory endpoints included the effects of treatment on serum TPO levels and on platelet function 
investigated by light transmission aggregometry and/or flow cytometry.  
 
Investigation of patients     
 
Studies performed to investigate patients at baseline and at each subsequent visit are detailed in 
Supplemental Methods.  
 
Statistical analysis 
 
Statistical analysis was performed as reported in Supplemental Methods.  
 
RESULTS 
 
Study population 
 
Twenty-four patients were enrolled between April 2015 and May 2017. They included 9 patients affected 
with MYH9-RD; 9 with ANKRD26-related thrombocytopenia (ANKRD26-RT);
19
 3 with thrombocytopenia 
caused by WAS mutations (2 with X-linked thrombocytopenia, XLT, and 1 with Wiskott-Aldrich syndrome, 
WAS);
20,21
 2 with monoallelic Bernard-Soulier syndrome (mBSS) caused by the Ala156Val mutation of 
GPIbα;
22
 1 with thrombocytopenia deriving from an ITGB3 mutation (ITGB3-RT).
23
 Patients’ mean platelet 
count was 40.4 x10
9
/L. Tables 1 and S4 describe the features of the study population at baseline.  
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Part 1 
 
Twenty-three patients completed the Part 1 of the study, whereas one patient with ANKRD26-RT 
discontinued treatment early because of an AE (see below).  
 
Primary endpoint. Response to Part 1 is summarized in Table 2 and detailed in Tables S5 and S6. Twenty-
one of the 23 evaluable patients (91.3%, 95%CI 72.0-98.9) obtained a response according to the study 
criteria: 11 patients (47.8%) achieved a major response and 10 (43.5%) a minor response. Two patients 
(8.7%) did not respond (one with ANKRD26-RT and the patient with ITGB3-RT). Most patients with MYH9-
RD and the two subjects with mBSS obtained a major response, whereas most patients with ANKRD26-RT 
and the three subjects with XLT/WAS achieved a minor response (Table 2).   
The mean platelet count at the end of Part 1 was 104.9 x10
9
/L (p<0.001 compared to baseline). The mean 
increase in platelet count with respect to baseline was 64.5 x10
9
/L (95%CI 43.7-85.3) overall, and 69.5 
x10
9
/L in the 21 responders. Table 2 and Figure 1 report the average increase in platelet count in the 
responders according to the different forms of IT.  
Ten of the 12 patients presenting spontaneous bleeding at baseline (83.3%) obtained complete remission 
of bleeding. In particular, all responders (major or minor response) achieved disappearance of bleeding 
symptoms if present at baseline. Of the two non-responders, the patient with ANKRD26-RT did not obtain 
any improvement of bleeding manifestations, whereas the patient with ITGB3-RT experienced a reduction 
of spontaneous bleeding (WHO grade from 2 to 1) following a mild increase in platelet count (from 62 to 78 
x10
9
/L).  
 
Eltrombopag dose. Ten patients (43.5%) achieved a major response with eltrombopag 50 mg/day and 
stopped therapy (Table 3). These patients were all the individuals with MYH9-RD or mBSS who obtained a 
major response and one subject with ANKRD26-RT. Thus, 13 patients (56.5%) switched to the dosage of 75 
mg/day. Treatment with the higher dose resulted in the achievement of a better response according to the 
study criteria in 4 of these subjects (Table 3). 
 
Exploratory endpoints. In vitro platelet aggregation in response to collagen, ADP, and ristocetin, was 
studied at the end of treatment in the 11 patients who achieved platelet counts >100 x10
9
/L. Platelet 
aggregation was normal in all the cases, except for two patients with MYH9-RD and one with mBSS who 
presented slightly reduced responses to the lowest ADP dose (Table S7). In 12 patients, platelet activation 
in response to ADP and TRAP was also assessed through flow cytometry as the induction of surface 
expression of P-selectin and of the activated form of GPIIb-IIIa.
24
 In these subjects, platelet activation at 
baseline was not significantly different compared to healthy controls. Overall, platelet responsiveness did 
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not significantly change after eltrombopag treatment with respect to baseline in the investigated patients 
(Figure S2).  
Mean serum TPO level at baseline was 177.8 pg/mL (SD 125). TPO levels were unchanged at the end of 
treatment both considering patients overall and stratifying them according to the different disorders or 
response to treatment (Table S8).   
 
Safety. We recorded 7 AEs in 5 patients (21%) (Table 4): all the AEs were grade 1 (mild) according to 
CTCAEv4.0. Four patients reported mild and transient headache and/or diffuse bone pain during the first 2-
3 days of treatment. One patient with ANKRD26-RT presented increased plasma creatinine at the 
assessment after 3 weeks of treatment with 50 mg/day. Although the AE was grade 1 (creatinine 1.6x 
above baseline), treatment was discontinued according to the study protocol. Further investigations 
showed that kidney dysfunction was due to urinary retention because of pre-existing benign prostatic 
hypertrophy and suggested that a causal relationship between eltrombopag administration and the AE is 
unlikely (see Table 4 for details). Results of ophthalmic assessment at the end of therapy were unchanged 
in all cases, including the 3 MYH9-RD patients presenting cataracts at baseline.  
 
Part 2 
 
Six patients had the criteria for enrollment to the Part 2 of the study. Two of them did not consent to long-
term treatment for logistic reasons, as they were not available to undergo the repeated visits planned by 
the study protocol. Thus, 4 patients entered the Part 2 (2 with MYH9-RD, 1 with WAS, 1 with ITGB3-RT). All 
of them presented at baseline with spontaneous mucosal hemorrhages WHO grade 2 or 3 (epistaxis, gum 
bleeding, menorrhagia, and/or hematochezia) (Table 5).  
 
Primary endpoint. Outcome of Part 2 is summarized in Table 5 and Figure 2. Three patients completed the 
16 weeks of therapy. All of them obtained a stable remission of mucosal bleeding throughout the 
treatment period. During eltrombopag administration, they experienced only very mild and occasional easy 
bruising (WHO grade 1), resulting in a minor response according to the study criteria. Concerning the 
patient with WAS, treatment was discontinued after 8 weeks because of exacerbation of cutaneous eczema 
(see below). During treatment, he obtained a complete remission of bleeding (WHO grade 0).  
 
Eltrombopag dose and HR-QoL. Two patients achieved the response with eltrombopag 25 mg/day, whereas 
two patients required 50 mg/day (Table 5, Figure 2).  
The reduction of bleeding symptoms was associated with an overall increase in the scores obtained with 
the FACT-TH18 and FACIT-F questionnaires (Table S9). The increase was evident in the two MYH9-RD 
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patients presenting the highest degree of bleeding tendency at baseline (WHO grade 3), whereas the two 
other patients obtained mild or no improvements.  
 
Exploratory endpoints. TPO levels of the 4 patients did not significantly change during Part 2. Platelet 
response to ADP and TRAP was assessed by flow cytometry in the two MYH9-RD patients and the WAS 
patient and did not show any significant changes with long-term eltrombopag (data not shown).      
 
Safety. The patient with WAS referred exacerbation of a pre-existing cutaneous eczema, which is a typical 
manifestation of the genetic disease. For this reason, eltrombopag was discontinued after 8 weeks of Part 
2. The AE was grade 2 according to CTCAEv3.0. The patient referred similar exacerbations of the eczema 
before enrollment to this study, which occurred without any apparent causes. However, the eczema 
improved some weeks after eltrombopag discontinuation, supporting a causal relationship with the 
treatment. No additional AEs were observed during Part 2 therapy. In particular, no occurrence or 
worsening of cataracts was observed, including the two patients with MYH9-RD presenting cataracts at 
baseline. 
 
Post-treatment assessments 
 
Twenty patients were re-evaluated 30 days after the end of Parts 1 or 2 (3 patients refused the visit). Post-
treatment assessments did not identify any AEs. Mean platelet count was 47.0 x10
9
/L (SD 26), similar to 
that at baseline in the same patients (40.9 x10
9
/L, SD 23). Bleeding tendency returned to that recorded at 
baseline in all the cases.  
 
DISCUSSION 
 
TPO-RAs represent an appealing treatment hypothesis for the majority of patients with thrombocytopenias 
of genetic origin. In fact, in most forms of IT, the megakaryocyte response to TPO is totally or partially 
preserved:
25,26
 therefore, TPO-RAs can potentially increase platelet production in many of these disorders. 
Moreover, in most IT patients, platelet function is normal or only partially impaired, so that increasing 
platelet count is expected to improve hemostasis.
25,27
 Patients with ITs may benefit from short-term 
courses of TPO-RAs as well as a prolonged treatment. Short-term courses may be given in preparation for 
elective surgery or other invasive procedures whenever platelet count is below the safe threshold for the 
specific procedure. In this context, TPO-RAs can replace perioperative platelet transfusions, thus preventing 
alloimmunization and the other risks of blood derivatives, and provide an option to increase platelet count 
even in patients refractory to platelet transfusions.
 10-12,14,15 
On the other hand, patients presenting with 
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clinically significant spontaneous bleeding may benefit from a long-term TPO-RAs administration to achieve 
an enduring remission of bleeding symptoms and reduce the risk of major hemorrhages. Despite these 
premises, clinical evidence on the efficacy and safety of TPO-RAs in ITs is very scarce.
28
 
 
The only previous prospective study tested short-term eltrombopag in MYH9-RD and showed that most 
patients responded to treatment without major side effects.
9
 The present trial investigates the response to 
short-term eltrombopag in a wider range of ITs, and provides information on the effects of a prolonged 
treatment in those patients presenting with clinically significant spontaneous hemorrhages.   
 
We gave short-term eltrombopag to patients affected with 5 different disorders: the large majority of them 
(91.3%) responded to the drug and the mean platelet count at the end of therapy was increased by 64.5 
x10
9
/L compared to baseline (p<0.001). However, we observed some differences in the degree of platelet 
response between the different forms of IT. Eltrombopag was highly effective in MYH9-RD, thus confirming 
and extending the results of the previous trial.
9
 All the MYH9-RD patients responded, most of them (78%) 
reached a platelet count >100 x10
9
/L, and the mean increase in platelet count compared to baseline was 
98.1 x10
9
/L. The two individuals with mBSS also achieved major responses with an increase in platelet 
count close to that of MYH9-RD subjects (80.5 x10
9
/L). Although 7 of the 8 evaluable patients with 
ANKRD26-RT responded to eltrombopag, the extent of platelet response was globally lower than in MYH9-
RD and mBSS: in fact, most ANKRD26-RT subjects obtained minor responses and the mean increase in 
platelet count in responders was 41.8 x10
9
/L. In the three XLT/WAS patients, results appeared similar to 
those of ANKRD26-RT: these patients reached a minor response with an average rise in platelet count of 
41.4 x10
9
/L. In spite of these differences, we believe that in all the above disorders the response to 
eltrombopag is highly significant for the use of the drug in preparation for surgery in clinical practice. In 
fact, current guidelines define a platelet count of 50 x10
9
/L as the threshold level recommended for major 
surgery, with the exception of neurosurgery and posterior eye surgery that require 100 x10
9
/L platelets.
4,5
 
In this view, while the response observed in MYH9-RD and mBSS appears a very good result, even the 
extent of the increase in platelet count obtained in ANKRD26-RT and XLT/WAS appears sufficient to avoid 
the use of platelet transfusions to prepare most patients for most surgical procedures.  
Finally, we treated only one patient with ITGB3-RT, who failed to achieve a platelet response according to 
the study criteria.   
 
All the patients who responded to Part 1, even achieving a minor response, showed a complete remission 
of bleeding symptoms whenever these were present at baseline. Even one of the two patients classified as 
non-responders according to the study criteria, experienced the remission of mucosal bleeding following a 
mild increase in platelet count. Remission of bleeding is consistent with the results of platelet function 
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studies during eltrombopag treatment: since platelet response to different agonists was normal or only 
slightly impaired, increasing platelet count was effective in improving hemostasis. Consistent with previous 
findings in XLT/WAS patients,
18
 flow cytometry showed that platelet responsiveness to ADP and TRAP does 
not significantly change with eltrombopag administration. 
 
Concerning the dosage of eltrombopag, 10 of the 11 patients achieving a major response obtained this 
result with 50 mg/day, while one patient required the dose of 75 mg/day. Overall, 10 of the 13 patients 
who were switched from 50 to 75 mg/day obtained a further increase of platelet count with the higher 
dose: 4 subjects reached a better response according to the study criteria, while 6 patients achieved only 
slightly higher platelet counts. All the patients with ANKRD26-RT or XLT/WAS, but one, required the switch 
to the higher dose that resulted in a higher platelet count in most cases. These data suggest that 75 mg/day 
is the most reasonable starting dose for preoperative eltrombopag in these two disorders.  
 
Effects of long-term eltrombopag administration were investigated in 4 patients presenting with frequent 
episodes of spontaneous mucosal bleeding. All of them achieved a stable remission of mucosal 
hemorrhages that persisted throughout the treatment period. In two patients, the reduction of 
spontaneous bleeding was associated with a very mild increase of platelet count (around 10 x10
9
/L). The 
same observation was previously made in a patient affected with WAS and treated with long-term 
eltrombopag because of severe bleeding symptoms.
17
 Two patients achieved remission of bleeding with the 
dosage of 25 mg/day, suggesting that, in some IT patients, clinical benefit can be maintained with 
prolonged administration of relatively low doses of eltrombopag. Interestingly, the two patients with the 
highest degree of bleeding tendency at baseline experienced not only a stable improvement of HR-QoL 
related to bleeding, but also an increase of the score measuring the subjective perception of fatigue.  
 
The observation that some patients obtained a significant reduction of bleeding tendency following a very 
mild increase in platelet count may suggest the hypothesis that eltrombopag improves some discrete 
platelet functions in addition to raise platelet concentration. As mentioned, overall we did not observe any 
significant change in platelet GPIIb-IIIa activation or P-selectin expression in response to ADP and TRAP 
after eltrombopag treatment compared to baseline, in 12 investigated patients. However, we cannot 
exclude that the drug could have improved some other mechanisms of platelet function
29
 in some patients, 
and further investigations are required to test this hypothesis.  
 
Short-term eltrombopag was globally well tolerated, with 17% of patients reporting mild and transient 
headache and/or bone pain at the beginning of treatment. In one ANKRD26-RT patient, we observed a mild 
increase in plasma creatinine; clinical investigation of this subject suggested that a causal relationship 
11 
 
between eltrombopag and this AE is unlikely. Regarding the long-term treatment, the patient affected with 
WAS experienced worsening of a pre-existing cutaneous eczema that required eltrombopag 
discontinuation after 14 weeks. This AE has never been described with the previous retrospective reports 
on WAS patients who received eltrombopag.
17,18
 No other AEs were recorded with long-term therapy.  
Eltrombopag has been associated with the occurrence of cataracts in patients with immune 
thrombocytopenia,
30
 and MYH9-RD is a syndromic disorder predisposing to cataracts.
31
 Thus, it is 
noteworthy that none of our MYH9-RD subjects showed development or progression of cataracts, not even 
the two patients who received long-term therapy and already presented cataracts at baseline.  
 
A previous study raised the suspicion that the TPO-RA romiplostim favors the progression to myeloid 
leukemia in patients with myelodysplastic syndromes (MDS).
32
 Subsequent trials of eltrombopag 
monotherapy in MDS did not observe safety issues in this regard:
33-35
 however, a trend for an increased risk 
of disease progression was reported in a study testing eltrombopag in association with azacitidine in 
intermediate- or high-risk MDS.
36
 These observations raise a concern on safety of TPO-RAs in ANKRD26-RT, 
a condition that increases the risk of myeloid malignancies.
37
 In the present study, short-term eltrombopag 
did not result in any changes of blood cells parameters or morphology (with the exception of platelet 
count) in ANKRD26-RT patients. However, further clinical data on this topic are needed, and caution should 
be used when treating individuals ANKRD26-RT or other ITs predisposing to hematological malignancies
38
 
with TPO-RAs, especially with long-term administration.  
 
In conclusion, this study shows that eltrombopag is effective in increasing platelet count in 4 different 
forms of ITs, which, taken together, affect more than 55% of patients with genetic thrombocytopenias.
28 
In 
most patients, short-term eltrombopag increased platelet count above the threshold for major surgery 
recommended by current guidelines,
4,5
 indicating that the drug can efficiently replace perioperative platelet 
transfusions in preparation for surgery or other invasive procedures. Although only 4 patients received 
long-term treatment, the results indicate that a prolonged eltrombopag therapy can induce a persistent 
remission of spontaneous bleeding. Both short- and long-term treatments were globally well tolerated. 
Although it is certainly required a greater amount of clinical data on the use of TPO-RAs in ITs, our results 
suggest that eltrombopag will probably have a central role in the treatment of thrombocytopenias of 
genetic origin. 
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Table 1. Main features of the study population at baseline.  
 
 Overall MYH9-RD ANKRD26-RT XLT/WAS mBSS ITGB3-RT 
Patients, no. 24 9 9 3 2 1 
M/F, no. of patients  14/10 2/7 7/2 3/0 2/0 0/1 
Age, years - mean [SD] 41.1 [13.7] 42.9 [14.7] 40.9 [15.1] 29.3 [6.8] 50 [5.7] 45 [-] 
Platelet count,
1
 x10
9
/L - mean [SD] 40.1 [22.4] 38.2 [22.7] 37.4 [22.2] 26.3 [15.8] 70 [1.4]  62 [-] 
Spontaneous bleeding, 
2
 no. of patients 13 3 7 1 1 1 
     WHO grade = 1, no.  7 0 7 0 0 0 
     WHO grade = 2, no. 4 1 0 1 1 1 
     WHO grade = 3, no 2 2 0 0 0 0 
Previous splenectomy,
3
 no. of patients 2 2 0 0 0 0 
 
Notes: 
1 
= as evaluated by phase-contrast microscopy in a counting chamber. 
2
 = spontaneous bleeding presented during the week preceding baseline evaluation 
according to World Health Organization (WHO) bleeding scale. 
3
 = previous splenectomy because of a mistaken diagnosis of immune thrombocytopenia.  
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Table 2. Response to Part 1 (primary endpoint), overall and according to the different forms of IT.  
 
 Overall MYH9-RD ANKRD26-RT WAS/XLT mBSS ITGB3-RT 
Evaluable patients, no. 23 9 8 3 2 1 
Response
1
       
Any response, % [95%CI] 
91.3 
[72.0-98.9] 
100.0 
[66.4-100.0] 
87.5 
[47.3-99.7] 
100.0 
[29.2-100.0] 
100.0 
[15.8-100.0] 
0 
[0-97.5] 
Major response, % [95%CI] 
47.8 
[26.8-69.4] 
77.8 
[40.0-97.2] 
25.0 
[3.2-65.1] 
0 
[0-70.8] 
100.0 
[15.8-100.0] 
0 
[0-97.5] 
Minor response, % [95%CI] 
43.5 
[23.2-65.5] 
22.2 
[2.8-60.0] 
62.5 
[24.5-91.5] 
100.0 
[29.2-100.0] 
0 
[0-84.2]2 
0 
[0-97.5] 
Platelet count
2
       
Baseline, x10
9
/L, mean [SD] 40.4 [22.8] 38.2 [22.7] 38.0 [23.7] 26.3 [15.8] 70.0 [1.4] 62.0 [-] 
End Part 1, x10
9
/L, mean [SD] 
104.9 [56.7]
§
 136.3 [68.0]
#
 75.5 [28.5]
§
 
67.7 [38.4] 150.5 [13.4] 78.0 [-] 
Mean increase, x10
9
/L [95%CI] 64.5 [43.7-85.3] 98.1 [53.3-142.9] 37.5 [24.1-50.8] 41.4 [22.1-104.8] 80.5 [27.5-188.5]
 
16.0 [-] 
Mean increase in responders,  x10
9
/L [95%CI] 69.5 [48.0-91.1] 98.1 [53.3-142.9] 41.8 [31.7-52.0] 41.4 [22.1-104.8] 80.5 [27.5-188.5] - 
Spontaneous bleeding (SB)
3
       
Patients with SB at baseline, no. 12 3 6 1 1 1 
Complete remission of SB end Part 1, % [95%CI] 83.3 [51.6-97.9] 100 [29.2-100] 83.3 [35.9-99.6] 100 [2.5-100] 100 [2.5-100] 0 [0-97.5] 
Partial reduction of SB end Part 1, % [95%CI] 8.3 [0.2-38.5] 0 [0.0-70.8] 0 [0.0-45.9] 0 [0.0-97.5] 0 [0.0-97.5] 100 [2.5-100] 
 
Notes: 
1
 = according to predefined study criteria. 
2
 = as evaluated by phase-contrast microscopy in a counting chamber. 
3
 = spontaneous bleeding presented during the 
week preceding evaluation according to World Health Organization (WHO) bleeding scale.  
§
 p<0.001 with respect to baseline.  
#
 p=0.001 with respect to baseline.    
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Table 3. Doses of eltrombopag administered during the Part 1.  
 
 Overall MYH9-RD ANKRD26-RT WAS/XLT mBSS ITGB3-RT 
Evaluable patients, no. 23  9 8 3 2 1 
Major response with 50 mg/day, no. (%) 10 (43.5) 7 (77.8) 1 (12.5) 0 2 (100) 0 
Switch to 75 mg/day, no. (%) 13 (56.5)  2 (22.2) 7 (87.5) 3 (100) 0 1 
Improvement of response with 75 mg/day
1
, no. 4 0 
2
§
 2
#
 
0 0 
 
Notes: 
1 
= achievement of a better response according to the study criteria with respect to treatment with 50 mg/day. 
§
 =1 patient achieved major response, 1 
achieved minor response. 
#
 = both patients achieved minor response. 
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Table 4. Adverse events (AEs) recorded during the Part 1. All the AEs were grade 1 according to CTCAEv4.0. 
 
Adverse event No. of AEs 
No. of 
patients (%) 
Description 
Any adverse event 7 5 (21%)  
Headache 4 4 (17%) 
Mild headache that resolved completely after 2 or 3 days. Some patients took 
low doses of acetaminophen with benefit.   
Bone pain 2 2 (8%) 
Mild diffuse bone pain that resolved completely after 3 or 4 days. Some 
patients took low doses of acetaminophen with benefit.   
Increased plasma creatinine 1 1 (4%) 
Increase 1.6-fold above baseline at the evaluation after 21 days of treatment. 
Treatment was stopped according to study protocol. Further investigations 
disclosed that the increased creatinine level was due to urinary retention 
because of concomitant benign prostatic hypertrophy. Creatinine level 
continued to progressively increase for two months after eltrombopag 
discontinuation and then completely resolved after specific urologic treatment. 
Worsening of prostatic hypertrophy has never been reported as an adverse 
reaction of eltrombopag treatment.
1 
Based on the clinical course of the 
disorder and data from literature, the investigators suggest that a causal 
relationship between eltrombopag administration and the AE is unlikely.  
 
Notes:
 1 
Eltrombopag (Revolade®) Product information available at  https://www.ema.europa.eu/en/medicines/human/  
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Table 5. Response to Part 2 in the 4 enrolled patients.  
 
Patient ID (Patient/Family)
1
 1/1 12/10 17/13 22/16 
Gender/age F/49 F/45 F/45 M/24 
Diagnosis MYH9-RD MYH9-RD ITGB3-RT WAS 
Treatment duration, weeks 16 16 16 8 
WHO bleeding score - baseline 3 3 2 2 
Bleeding symptoms - baseline 
Easy bruising 
Petechiae 
Gum bleeding 
Epistaxis 
Easy bruising 
Gum bleeding 
Menorrhagia 
Easy bruising 
Menorrhagia 
Easy bruising 
Epistaxis 
Hematochezia 
Platelet count - baseline, x10
9
/L 14 38 62 9 
WHO bleeding score - end Part 2
2
 1 1 1 0 
Bleeding symptoms - end Part 2 Easy bruising Easy bruising Easy bruising None 
Platelet count - end Part 2,
3
 x10
9
/L 75 76 70 19 
Eltrombopag dose - end Part 2, mg/day 50 25 25 50 
Response to Part 2
4
 Minor Minor Minor Major 
 
Notes: 
1
 = please see Table S4.  
2
 = spontaneous bleeding presented during the 2 weeks preceding the last on-treatment visit according to WHO bleeding scale. 
3 
= as evaluated at the last on-treatment visit by phase-contrast microscopy in a counting chamber. 
4 
= according to predefined study criteria. 
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FIGURE LEGENDS 
 
Figure 1. Mean increase in platelet count in the responders to the Part 1 treatment. Patients are 
categorized according to the diagnosis of the specific form of IT. MYH9-RD: MYH9-related disease. mBSS: 
monoallelic Bernard-Soulier syndrome. ANKRD26-RT: ANKRD26-related thrombocytopenia. XLT/WAS: X-
linked thrombocytopenia / Wiskott-Aldrich syndrome. Mean values of platelet count at baseline and at the 
end of Part 1 treatment along with their 95% confidence intervals (95%CI) are reported in the grey box.  
 
Figure 2. Effects of Part 1 and Part 2 treatments in the 4 individuals who received long-term 
eltrombopag. Figure summarizes the effects of eltrombopag administration on bleeding symptoms 
according to the World Health Organization (WHO) bleeding scale and on platelet count. Patients 1/1 and 
12/10 are affected with MYH9-related disease, patient 17/13 with ITGB3-RT, and patient 22/16 with 
Wiskott-Aldrich syndrome (see Table 5).  


1 
 
Supplemental data of the paper entitled “Eltrombopag for the treatment of inherited 
thrombocytopenias: a phase 2 clinical trial”. 
 
SUPPLEMENTAL METHODS 
 
Inclusion and exclusion criteria 
 
Patients were eligible for the study if they fulfilled all of the following criteria: diagnosis of one of the forms 
of IT listed in Table S2 confirmed by molecular analysis; age 16-70 years; platelet count <80 x109/L. 
Exclusion criteria are listed in Table S2.  
 
Investigation of patients     
 
Table S3 details the studies performed to investigate patients at baseline and at each subsequent visit (Part 
1: after 3 weeks of treatment and, in some patients, 6 weeks of treatment, and post-treatment assessment 
at 30 days unless patients entered Part 2. Part 2: after 4, 8, 12, and 16 weeks of treatment and post-
treatment assessment at 30 days). Platelet count was measured by both automated cell counters and 
phase-contrast microscopy in a counting chamber. Since electronic cell counters underestimate platelet 
count in patients with ITs characterized by marked platelet macrocytosis,1,2 only platelet count measured 
by microscopy was used for the purposes of this study. Spontaneous bleeding was measured according to 
the WHO bleeding scale:3 grade 0, no bleeding; grade 1, cutaneous bleeding only; grade 2, mild blood loss; 
grade 3, gross blood loss; grade 4, debilitating blood loss.  
Adverse events (AEs) were coded and graded according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events version 4.0 (CTCAEv4.0). Patients’ health-related quality of life (HR-
QoL) was assessed in patients eligible to Part 2 at baseline and at each subsequent visit as detailed below.  
 
Measurement of serum thrombopoietin levels  
 
Measurement of serum thrombopoietin (TPO) levels was centralized at the IRCCS Policlinico San Matteo, 
Pavia. Serum TPO levels were measured using the Quantikine ELISA Human Thrombopoietin Immunoassay 
Kit (R&D system, Minneapolis, USA) according to the manufacturer's instructions.4   
 
In vitro platelet aggregation 
 
2 
 
In vitro platelet aggregation in response to collagen, adenosine diphosphate (ADP) and ristocetin was 
assessed in patients who obtained platelet count >100 x109/L, with the densitometric method of Born, as 
described.5 
 
Flow cytometry investigation of platelet activation  
 
Platelet activation in response to different agonists was investigated by flow cytometry as reported.6 
Briefly, aliquots of whole blood were incubated with moAbs and either ADP 1 μM, ADP 5 μM, TRAP 25 μM, 
or vehicle HEPES buffer alone, for 10 minutes at 37°C, and then fixed with paraformaldehyde. The following 
moAbs were used: PAC1, which specifically binds to the activated conformation of GPIIb-IIIa (Becton 
Dickinson, San Josè, CA, USA); CLB-Thromb/6 against P-selectin (CD62P) (Immunotech, Marseille, France); 
P2 against GPIIb-IIIa (CD41) (Immunotech). Platelets were gated by GPIIb-IIIa (CD41) expression. Platelet 
activation was expressed as the ratio between mean fluorescence intensity (MFI) measured after 
stimulation with each agonist and MFI measured after incubation with the buffer alone. Patients’ samples 
were processed in parallel with those of 25 healthy controls. Data represent the mean ± SD of two 
independent analyses. 
 
Assessment of patients’ health-related quality of life  
 
Patients’ health-related quality of life (HR-QoL) was assessed in patients eligible to Part 2 at baseline and at 
each subsequent visit. HR-QoL was measured through the administration of three validated questionnaires 
with complementary significance. 3,7-10 The 18-item Functional Assessment of Cancer Therapy-
Thrombocytopenia (FACT-Th18) was used to assess the effect of bleeding on HR-QoL.7,9 The fatigue 
subscale of the Functional Assessment of Chronic Illness Therapy (FACIT-F) questionnaire was used to focus 
on the perception of fatigue.8,9 The acute recall version of the short form-36, version 1 (SF-36v1) measured 
general HR-QoL.10  
 
Statistical analysis 
 
Stata 15.1 (StataCorp, College Station, TX) was used for all analyses. The rate of response and its 95% exact 
binomial confidence interval (95%CI) was computed. We compared baseline to end of Part 1 platelet counts 
with the Student t test for paired data (after graphically assessing normality of the distribution) and 
computed the mean change and its 95%CI (normal based). 
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SUPPLEMENTAL TABLES 
 
 
Table S1. Centres that participated in this study.  
 
 
- IRCCS Policlinico San Matteo Foundation, Pavia, Italy (sponsor and coordinating centre). 
- Azienda Ospedaliera di Perugia, Perugia, Italy. 
- Azienda Ospedaliera di Padova, Padova, Italy. 
- IRCCS Policlinico Agostino Gemelli Foundation, Roma, Italy.  
- Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.  
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Table S2. Inclusion and exclusion criteria for the present study. 
 
 
INCLUSION CRITERIA 
 
Patients were considered for enrollment if they fulfilled all of the following 4 criteria. 
 
1 - Diagnosis of one of the following forms of inherited thrombocytopenia confirmed by molecular 
analysis: 
- MYH9-related disease (OMIM 155100, 605249, 153640, 153650)  
- Bernard-Soulier Syndrome deriving from monoallelic mutations (OMIM 153670) 
- Wiskott-Aldrich syndrome (OMIM 301000).  
- X-linked thrombocytopenia (OMIM 313900).  
- X-linked thrombocytopenia with thalassemia (OMIM 314050).  
- Dyserythropoietic anemia with thrombocytopenia (OMIM 300367).  
-  ITGA2B/ITGB3-related thrombocytopenia (OMIM 187800). 
- ANKRD26-related thrombocytopenia (OMIM 188000). 
- TUBB1-related thrombocytopenia (OMIM 613112) 
- ACTN1-related thrombocytopenia (OMIM 615193) 
- GFI1B-related thrombocytopenia (OMIM 187900) 
- CYCS-related thrombocytopenia (OMIM 612004) 
- SLFN14-related thrombocytopenia (OMIM not available) 
 
2 - Age ≥ 16 years and ≤ 70 years 
3 - Average platelet count at baseline and during the previous year less than 80 x109/L   
4 - Written informed consent 
 
EXCLUSION CRITERIA 
 
Patients were excluded from enrollment if they presented one or more of the following criteria. 
 
- Hypersensitivity to eltrombopag or one of the excipients.  
- History of thromboembolic events. 
- Treatment with anti-platelet drugs or other drugs affecting platelet function and/or with anticoagulants.  
- Concurrent diseases or conditions that significantly increase the risk of thromboembolic events. 
- Moderate to severe liver failure (Child-Pugh score ≥ 5). 
- Altered renal function as defined by creatinine ≥ 2 mg/dL 
- Previous or concurrent clonal disorders of the myeloid series (acute myeloid leukemias and 
myelodysplastic syndromes).  
- Females who are pregnant or nursing (a negative pregnancy test was required before enrolment of fertile 
women). 
- Formal refusal of any recommendations for a safe contraception. 
- Alcohol or drug addiction. 
- Any other disease or condition that by the advice of the responsible physician would make the treatment 
dangerous for the patient or would make the patient ineligible for this study, including physical, 
psychiatric, social and behavioral problems. 
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Table S3. Studies for investigation of patients at baseline and at each subsequent on-treatment and post-
treatment assessments (unless otherwise specified in notes).  
 
 
- Medical history 
- Physical examination 
- Evaluation of bleeding tendency according to WHO bleeding scale during the previous 1 or 2 weeks 1 
- Complete blood counts and differential by automated cell counter 
- Measurement of platelet count by phase-contrast microscopy in a counting chamber 
- Peripheral blood smear examination 
- Measurement of plasma aspartate transaminase (AST), alanine transaminase (ALT), total and 
fractionated bilirubin, and creatinine 
- Urine analysis 
- Ophthalmic assessment to monitor for cataracts or other ocular changes2 
- Measurement of serum thrombopoietin level 
- Assessment of health-related quality of life with the FACT-Th18, FACIT-F, and SF-36v1 questionnaires3 
- Investigation of in vitro platelet aggregation in response to collagen (5 and 20 µg/mL), ADP (2 or 5 and 20 
µM), and ristocetin (1.5 mg/mL)4  
 
 
Notes: 1 = previous 1 week at baseline and during Part 1, previous 2 weeks during Part 2.  
2 =performed only at baseline, at the end of Parts 1 and 2, and at the assessment 30 days after the end of 
Parts 1 and 2. 
 3 = performed only at baseline, during the Part 2, and at the assessment 30 days after the end of Part 2. 
4 = performed at the end of the Parts 1 and 2 whenever platelet count was over 100 x109/L.  
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Table S4. Features of the study population at baseline. 
 
Patient no./ 
Family no. 
Gender / 
age 
Diagnosis 
Causative 
mutation 
Automated 
platelet 
count,
1
 
x10
9
/L 
Microscopic 
platelet 
count,
2
 
x10
9
/L 
WHO 
bleeding 
score
3
 
Bleeding 
symptoms
4
 
Other disease features
5
 
1/1 F/49 MYH9-RD 
MYH9 
c.279C>G 
4 14 3 EB, Pe, GB, Ep 
Nephropathy, sensorineural 
deafness, cataracts 
2/2 M/57 ANKRD26-RT 
ANKRD26 
c.-125 T>G 
22 17 1 EB - 
3/3 F/55 MYH9-RD 
MYH9 
 c.3493C>T 
58 69 2 EB, GB Sensorineural deafness 
4/4 M/63 ANKRD26-RT 
ANKRD26 
c.-118C>A 
37 33 1 EB - 
5/5 M/43 ANKRD26-RT 
ANKRD26 
c.-125T>G 
13 12 1 EB, Pe - 
6/6 M/46 mBSS 
GPIBA 
c.515C>T 
65 69 2 GB, Ep, Hm - 
7/7 F/24 ANKRD26-RT 
ANKRD26 
c.-128G>A 
42 37 1 EB - 
8/8 M/54 mBSS 
GPIBA 
c.515C>T 
67 71 0 - - 
9/9 M/40 ANKRD26-RT 
ANKRD26 
c.-116C>T 
67 63 1 EB - 
10/2 M/54 ANKRD26-RT 
ANKRD26 
c.-125T>G 
33 33 1 EB - 
11/2 M/19 ANKRD26-RT 
ANKRD26 
c.-125T>G 
55 53 1 EB - 
12/10 F/45 MYH9-RD 
MYH9 
c.4270G>C 
23 38 3 EB, GB, Me 
Nephropathy, sensorineural 
deafness, cataracts 
13/11 M/37 XLT/WAS 
WAS 
c.257G>A 
11 30 0 - - 
14/11 M/27 XLT/WAS 
WAS 
c.257G>A 
52 40 0 - - 
15/12 M/19 MYH9-RD 
MYH9 
c.2104C>T 
16 12 0 - 
Nephropathy, sensorineural 
deafness 
16/12 M/46 MYH9-RD 
MYH9 
c.2104C>T 
67 70 0 - 
Nephropathy, sensorineural 
deafness 
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17/13 F/45 ITGB3-RT 
ITGB3 
c.2134+1G>C 
 
55 62 2 EB, Me - 
18/7 F/39 ANKRD26-RT 
ANKRD26     
c.-128G>A 
78 75 0 - - 
19/14 F/47 MYH9-RD 
MYH9 
 c.5797C>T 
61 57 0 - - 
20/14 F/34 MYH9-RD 
MYH9 
 c.5797C>T 
30 27 0 - - 
21/15 F/25 MYH9-RD 
MYH9 
 c.3485G>C 
23 18 0 -  
22/16 M/24 XLT/WAS 
WAS 
c.777+3inst 
10 9 2 EB, Ep, Hm 
Cutaneous eczema, 
immunodeficiency 
23/17 F/66 MYH9-RD 
MYH9 
 c.4270G>A 
37 39 0 - Cataracts 
24/18 M/29 ANKRD26-RT 
ANKRD26   
c.-126T>G  
14 14 0 - - 
 
Notes: 1 = as evaluated by standard automated cell counters. 2 = as evaluated by phase-contrast microscopy in a counting chamber. Only platelet count 
measured with this method was used for the purposes of this study. 3 = spontaneous bleeding presented during the week preceding baseline evaluation 
according to World Health Organization (WHO) bleeding scale.  4 = EB, easy bruising. Pe, petechiae. GB, gum bleeding. Ep, epistaxis. Me, menorrhagia. Hm, 
hematochezia. 5 = other disease features in patients with syndromic forms of ITs.  
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Table S5. Response to Part 1 of the study.  
 
Patient no./ 
Family no. 
Gender / 
age 
Diagnosis 
Maximal 
eltrombopag 
dose
1
 
Platelet count - 
baseline,
2
  
x10
9
/L 
Platelet count - 
end treatment,
2
  
x10
9
/L 
WHO bleeding 
grade - baseline
3
 
WHO bleeding 
grade - end 
treatment
3
 
Response
4
 
1/1 F/49 MYH9-RD 75 mg 14 80 3 0 Minor 
2/2 M/57 ANKRD26-RT 75 mg 17 49 1 0 Minor 
3/3 F/55 MYH9-RD 50 mg 69 300 2 0 Major 
4/4 M/63 ANKRD26-RT 75 mg 33 82 1 0 Minor 
5/5 M/43 ANKRD26-RT 75 mg 12 35 1 0 Minor 
6/6 M/46 mBSS 50 mg 69 141 2 0 Major 
7/7 F/24 ANKRD26-RT 75 mg 37 91 1 0 Minor 
8/8 M/54 mBSS 50 mg 71 160 0 0 Major 
9/9 M/40 ANKRD26-RT 75 mg 63 109 1 0  Major 
10/2 M/54 ANKRD26-RT 50 mg 33 35 1 0 Not evaluable 
11/2 M/19 ANKRD26-RT 75 mg 53 60 1 1 No response 
12/10 F/45 MYH9-RD 50 mg 38 120 3 0 Major 
13/11 M/37 WAS/XLT 75 mg 30 96 0 0 Minor 
14/11 M/27 WAS/XLT 75 mg 40 83 0 0 Minor 
15/12 M/19 MYH9-RD 75 mg 12 77 0 0 Minor 
16/12 M/46 MYH9-RD 50 mg 70 122 0 0 Major 
17/13 F/45 ITGA2B/ITGB3-RT 75 mg 62 78 2 1 No response 
18/7 F/39 ANKRD26-RT 50 mg 75 115 0 0 Major 
19/14 F/47 MYH9-RD 50 mg 57 110 0 0 Major 
20/14 F/34 MYH9-RD 50 mg 27 178 0 0 Major 
10 
 
21/15 F/25 MYH9-RD 50 mg 18 114 0 0 Major 
22/16 M/24 WAS/XLT 75 mg 9 24 2 0 Minor 
23/17 F/66 MYH9-RD 50 mg 39 126 0 0 Major 
24/18 M/29 ANKRD26-RT 75 mg 14 63 0 0 Minor 
 
Notes: 1 = 50mg, 50 mg/day for 3 weeks. 75mg, 50 mg/day for 3 weeks followed by 75 mg/day for 3 additional weeks. 2 = as evaluated by phase-contrast 
microscopy in a counting chamber. 3 = spontaneous bleeding presented during the week preceding evaluation according to World Health Organization (WHO) 
bleeding scale. 4 = according to predefined study criteria.  
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Table S6. Results of platelet count measurements during the Part 1 of the study.  
 
   
 
Platelet count x10
9
/L
1
 
 
Patient no./ 
Family no. 
Gender / 
age 
Diagnosis Baseline 
After 3 weeks 
treatment with 
eltrombopag  
50 mg/day 
After 3 additional 
weeks treatment 
with eltrombopag 
75 mg/day 
30 days after 
treatment  
discontinuation 
1/1 F/49 MYH9-RD 14 60 80 nd
2
 
2/2 M/57 ANKRD26-RT 17 40 49 28 
3/3 F/55 MYH9-RD 69 300 - 80 
4/4 M/63 ANKRD26-RT 33 57 82 30 
5/5 M/43 ANKRD26-RT 12 23 35 15 
6/6 M/46 mBSS 69 141 - 90 
7/7 F/24 ANKRD26-RT 37 68 91 46 
8/8 M/54 mBSS 71 160 - 64 
9/9 M/40 ANKRD26-RT 63 82 109 nd
3
 
10/2 M/54 ANKRD26-RT 33 35 - - 
11/2 M/19 ANKRD26-RT 53 58 60 56 
12/10 F/45 MYH9-RD 38 120 - nd
2
 
13/11 M/37 WAS/XLT 30 54 96 30 
14/11 M/27 WAS/XLT 40 56 83 37 
15/12 M/19 MYH9-RD 12 64 77 22 
16/12 M/46 MYH9-RD 70 122 - 110 
17/13 F/45 ITGA2B/ITGB3-RT 62 68 78 nd
2
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18/7 F/39 ANKRD26-RT 75 115 - 69 
19/14 F/47 MYH9-RD 57 110 - 52 
20/14 F/34 MYH9-RD 27 178 - 24 
21/15 F/25 MYH9-RD 18 114 - 22 
22/16 M/24 WAS/XLT 9 21 24 nd
2
 
23/17 F/66 MYH9-RD 39 126 - nd
3
 
24/18 M/29 ANKRD26-RT 14 47 63 16 
 
Notes: 1 = as evaluated by phase-contrast microscopy in a counting chamber. 2 = not determined (nd) as the patient was admitted to the Part 2 of the study (see 
Figure 2). 3 = not determined (nd) as the patient refused the follow-up visit.  
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Table S7. In vitro platelet aggregation at the end of Part 1 in the 11 patients who achieved a platelet count above 100 x109, maximal extent (percentage). 
Patients are reported according to the laboratories that performed the analysis, as the normal ranges of the assay are slightly different according to the 
laboratories of the different participating centres.  
 
 
Patient  
ID1 
Patient  
diagnosis 
Platelet  
count,2 
x109/L 
Collagen,  
4 µg/mL 
Collagen,  
20 µg/mL 
ADP,  
2 or 5 µM3 
ADP,  
20 µM 
Ristocetin,  
1.5 mg/mL 
Pavia laboratory 
3/3 MYH9-RD 300 87% nd 67% nd 85% 
6/6 mBSS 141 96% nd 21% 86% 96% 
8/8 mBSS 160 85% nd 58% 84% 100% 
9/9 ANKRD26-RT 120 74% nd 70% nd 84% 
12/10 MYH9-RD 109 88% nd 85% nd 98% 
Perugia laboratory 16/12 MYH9-RD 122 nd 182% nd 104% nd 
Padova laboratory 
18/7 ANKRD26-RT 115 94%  nd 98% nd 98% 
19/14 MYH9-RD 110 95%  nd 89% nd 96% 
20/14 MYH9-RD 178 89% nd 20% 85% 99% 
21/15 MYH9-RD 114 92% nd 15% 79% 104% 
Roma laboratory 23/17 MYH9-RD 126 74% 75% 75% 73% 69% 
 
Normal values (range): 
Pavia laboratory: collagen 66-88%, ADP 43-76%, ristocetin 67-90%. 
Perugia laboratory: collagen 57.8-80.2%, ADP 43.2-73.2%, ristocetin 70-90% 
Padova laboratory: collagen 44-86%, ADP 57-101%, ristocetin 76-90% 
Roma laboratory: collagen 70-130%, ADP 58-90 %, ristocetin >60 % 
Notes: 1 = please see Table S4.  2 = platelet count at the end of Part 1. 3 = the lowest dose of adenosine diphosphate (ADP) was 5 µM in the Pavia and Roma 
laboratories, and the 2 µM in the Padova laboratory.  
Abbreviation: nd = not determined.  
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Table S8. TPO levels at baseline, at the end of Part 1, and at the post-treatment assessment 30 days after the end of Part 1.  
 
 Overall MYH9-RD ANKRD26-RT WAS/XLT mBSS ITGB3-RT 
Baseline (n=23 patients) 
mean (SD), pg/mL 
177.8 (125) 139.3 (104) 274.3 (129) 141.8 (33) 54.1 (13) 69 (-) 
End treatment (n=23 patients) 
mean (SD), pg/mL 
182.1 (209) 109.6 (117) 315.8 (287) 128.5 (33) 72.0 (20) 73 (-) 
Post-treatment (n=17 patients) 
mean (SD), pg/mL 
173.9 (178) 104.7 (73) 310.5 (259) 151.0 (65) 63.0 (15) nd 
 
Notes: 1 = 6 patients did not undergo assessment 30 days after the end of Part 1 (2 refused the post-treatment visit and 4 entered the Part 2).   
Normal values, as determined in a cohort of 100 consecutive healthy individuals, are 72.7 pg/mL (mean, SD 47.1). 
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Table S9. Results of the assessment of health-related quality of life (HR-QoL) in the 4 patients enrolled to 
the Part 2. 
 
 
Mean (SD) 
Patient 1 
(MYH9-RD) 
Patient 2 
(MYH9-RD) 
Patient 3 
(WAS) 
Patient 4 
(ITGB3-RT) 
FACT-TH18 (Trial Outcome Index) 
Baseline  83.7 (23.9) 55.7 72 102 105 
Week 4 102.2 (6.6) 98.4 96 103.4 111 
Week 8 100 (8.6) 96.3 92 99.8 112 
Week 12 101.4 (8.4) 98.3 95 nd 111 
Week 16 102.4 (8.4) 96.3 99 nd 112 
Post-treatment 81.7 (27.6) 53.2 63 102 108.5 
% at week 16 
vs. baseline1 
113% 173% 137% 98% 107% 
FACIT-F 
Baseline 36.0 (12.2) 25 26 48 45 
Week 4 43.5 (5.3) 39 39 49 47 
Week 8 44.7 (5.1) 38 44 50 47 
Week 12 44.3 (4.0) 40 45 nd 48 
Week 16 44.7 (5.9) 38 49 nd 47 
Post-treatment 39.0 (10.5) 25 37 48 46 
% at week 16 
vs. baseline1 
124% 152% 188% 104% 104% 
SF-36v.1 
 PCS MCS PCS MCS PCS MCS PCS MCS PCS MCS 
Baseline 44.9 (9) 50.7 (5) 47.3 43.3 30.9 51.1 50.7 55.9 50.8 52.7 
Week 4 50.8 (3) 48.7 (6) 46.8 48.6 50.4 40.0 51.3 53.8 54.7 52.6 
Week 8 49.8 (5) 52.7 (3) 42.7 49.7 50.2 51.7 51.5 57.0 54.7 52.6 
Week 12 49.6 (7) 52.7 (3) 42.9 49.7 49.2 54.4 nd nd 56.6 53.9 
Week 16 50.3 (7) 54.1 (5) 43.5 49.7 50.5 59.6 nd nd 57.0 53.0 
Post-treatment 46.0 (8) 45.6 (8) 47.3 43.3 37.5 38.9 nd nd 53.3 54.7 
% week 16 vs. 
baseline1 
112% 107% 92% 115% 163% 117% 102% 102% 112% 101% 
 
Notes: 
FACT-Th18 = The 18-item Functional Assessment of Cancer Therapy-thrombocytopenia questionnaire, 
which measures the effect of bleeding on HR-QoL. 
FACIT-F = The Fatigue subscale of the Functional Assessment of Chronic Illness Therapy questionnaire, 
which measures the perception of fatigue. 
SF-36v1 = The acute recall version of the Short Form-36, version 1, which measures the general HR-QoL. 
Data are reported separately for the Physical Component Summary (PCS) and the Mental Component 
Summary (MCS).  
1 = percentage variation at week 16 (end of Part 2) with respect to the baseline value.  
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SUPPLEMENTAL FIGURES 
 
 
FIGURE S1 
 
 
                              
 
 
Figure S1. Schedule for dose adjustments of eltrombopag during the Part 2 of the study.  
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FIGURE S2 
 
   
 
 
FIGURE S2. Platelet responsiveness to ADP and TRAP in 12 patients at baseline and at the end of Part 1. 
Flow cytometry study of platelet activation in response to ADP and TRAP was carried out in 12 patients at 
baseline and at the end of Part 1: investigated patients were 4 subjects with MYH9-RD, 5 with ANKRD26-RT, 
2 with mBSS, and 1 with WAS. Results obtained in patients were compared with those of 25 healthy 
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controls who were processed in parallel. Platelet surface expression of P-selectin and of the activated form 
of GPIIb-IIIa (PAC1 antibody binding) was measured after incubation with ADP 1 µM, ADP 5 µM, TRAP 25 
µM, or the vehicle HEPES buffer alone. Platelet activation is expressed as the ratio between the mean 
fluoresce intensity (MFI) measured after stimulation with each agonist and the MFI measured after 
incubation with the buffer alone (resting platelets). Filled circles with connecting lines represents the values 
obtained in individual patients at baseline and after treatment; open circles represent the values obtained 
in healthy controls. Thick lines indicate the mean values. Platelet responses to ADP and TRAP were not 
significantly different in patients at baseline compared to controls. Platelet responses to the agonists did 
not significantly change at the end of Part 1 treatment with respect to the baseline (Student t test for 
paired data).  
 
 
